Compare Ascendis Pharma A/S (ASND) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Corning Incorporated — how do they compare? Ascendis Pharma A/S trades at $263.66 (market cap $17.74B), while Corning Incorporated trades at $184.5 (market cap $164.29B). The key difference: Corning Incorporated is far larger — about 9.3× Ascendis Pharma A/S's market cap, and Corning Incorporated pays a 0.59% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GLW | |
|---|---|---|
Market Cap | $17.74B | $164.29B |
Sector | Health | Technology |
52-Week High | $277.18 | $255.79 |
52-Week Low | $163.32 | $51.60 |
Enterprise Value | $18.11B | $172.46B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
GLW trades at $190.85, down 0.87% on the day, with a bullish technical signal supported by moving averages and oversold RSI-6 at 12.45. Recent earnings beats in Q3 2025-Q1 2026 and strong 2025 revenue growth to $15.63B highlight fundamental strength. Analyst consensus is bullish with a $208.60 price target, though high P/E of 91.77 raises valuation concerns. News outlets like Barron's (July 10, 2026) note AI-driven partnerships as a key catalyst amid recent volatility.
Outlook remains positive with AI infrastructure demand fueling growth, but risks include elevated debt levels and competitive pressures. The stock offers a dividend yield of approximately 0.29% with consistent payouts. Investors should weigh robust earnings momentum against rich valuations and macroeconomic headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
